Algorae Pharmaceuticals (Algorae Pharmaceuticals) Accumulated other comprehensive income (loss) : $0.44 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Algorae Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Algorae Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $0.44 Mil.

Algorae Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Dec. 2022 ($2.50 Mil) to Jun. 2023 ($2.85 Mil) but then declined from Jun. 2023 ($2.85 Mil) to Dec. 2023 ($0.44 Mil).

Algorae Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Jun. 2021 ($2.90 Mil) to Jun. 2022 ($2.69 Mil) but then increased from Jun. 2022 ($2.69 Mil) to Jun. 2023 ($2.85 Mil).

Algorae Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Algorae Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Algorae Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

2.87

2.65

2.90

2.69

2.85

Algorae Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															2.75	2.69	2.50	2.85	0.44

Algorae Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Algorae Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Algorae Pharmaceuticals (Algorae Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (OTCPK:LVCLY) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

LVCLF:USA LHI0:Germany 1AI:Australia

Address

201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000

Website

https://www.algoraepharma.com

Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (Algorae Pharmaceuticals) Headlines

From GuruFocus

Living Cell Technologies Ltd at Vertical Events Gold Coast Investment Showcase Transcript

By GuruFocus Research • 02-14-2024

Living Cell Technologies Ltd at Vertical Events Gold Coast Investment Showcase Transcript

By GuruFocus Research • 02-14-2024